221 related articles for article (PubMed ID: 37302383)
1. NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors.
Khanmohammadi S; Ramos-Molina B; Kuchay MS
Diabetes Metab Syndr; 2023 Jul; 17(7):102788. PubMed ID: 37302383
[TBL] [Abstract][Full Text] [Related]
2. 20(S)-Protopanaxatriol ameliorates MAFLD by inhibiting NLRP3 inflammasome.
Lu B; Wang D; Xie D; Wu C; Sun M
Eur J Pharmacol; 2023 Feb; 940():175468. PubMed ID: 36566009
[TBL] [Abstract][Full Text] [Related]
3. Activation and regulation mechanisms of NOD-like receptors based on structural biology.
Ohto U
Front Immunol; 2022; 13():953530. PubMed ID: 36189327
[TBL] [Abstract][Full Text] [Related]
4. NOD-like receptors and inflammasomes: A review of their canonical and non-canonical signaling pathways.
Platnich JM; Muruve DA
Arch Biochem Biophys; 2019 Jul; 670():4-14. PubMed ID: 30772258
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of NOD-like receptors and regulation of NLRP3 inflammasome activation in Toxoplasma gondii-infected human small intestinal epithelial cells.
Chu JQ; Gao FF; Wu W; Li C; Pan Z; Sun J; Wang H; Huang C; Lee SH; Quan JH; Lee YH
Parasit Vectors; 2021 Mar; 14(1):153. PubMed ID: 33712075
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
7. Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications.
Yu L; Gao F; Li Y; Su D; Han L; Li Y; Zhang X; Feng Z
Biomed Pharmacother; 2024 Jun; 175():116724. PubMed ID: 38761424
[TBL] [Abstract][Full Text] [Related]
8. [Latest Findings on NOD-Like Receptor Family Pyrin Domain Containing Protein 3 Inflammasome and Bone and Articular Diseases].
Wang JH; Zou SJ; Xie J; Zhou CC
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):679-684. PubMed ID: 37248605
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
10. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptors participate in carcinogenesis signaling pathways by directly regulating NOD-like receptors.
Fan W; Gao X; Ding C; Lv Y; Shen T; Ma G; Yan L; Song S
Biochem Biophys Res Commun; 2019 Apr; 511(2):468-475. PubMed ID: 30797557
[TBL] [Abstract][Full Text] [Related]
12. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
13. [The role of NOD-like receptors (NLRs) in the pathogenesis of metabolic diseases].
Grzywa RH
Postepy Biochem; 2017; 63(3):205-209. PubMed ID: 29294265
[TBL] [Abstract][Full Text] [Related]
14. NLRs and inflammasome signaling in opioid-induced hyperalgesia and tolerance.
Zare N; Sharafeddin F; Montazerolghaem A; Moradiannezhad N; Araghizadeh M
Inflammopharmacology; 2024 Feb; 32(1):127-148. PubMed ID: 38153538
[TBL] [Abstract][Full Text] [Related]
15. Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: Histological and immunohistochemical study.
Mohamed IN; Sarhan NR; Eladl MA; El-Remessy AB; El-Sherbiny M
Acta Histochem; 2018 Apr; 120(3):242-254. PubMed ID: 29482933
[TBL] [Abstract][Full Text] [Related]
16. Bee's honey attenuates non-alcoholic steatohepatitis-induced hepatic injury through the regulation of thioredoxin-interacting protein-NLRP3 inflammasome pathway.
Xiao J; Liu Y; Xing F; Leung TM; Liong EC; Tipoe GL
Eur J Nutr; 2016 Jun; 55(4):1465-77. PubMed ID: 26133299
[TBL] [Abstract][Full Text] [Related]
17. Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation.
Hughes FM; Vivar NP; Kennis JG; Pratt-Thomas JD; Lowe DW; Shaner BE; Nietert PJ; Spruill LS; Purves JT
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F299-308. PubMed ID: 24285499
[TBL] [Abstract][Full Text] [Related]
18. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
Sui YH; Luo WJ; Xu QY; Hua J
World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141
[TBL] [Abstract][Full Text] [Related]
19. The NLR family of innate immune and cell death sensors.
Sundaram B; Tweedell RE; Prasanth Kumar S; Kanneganti TD
Immunity; 2024 Apr; 57(4):674-699. PubMed ID: 38599165
[TBL] [Abstract][Full Text] [Related]
20. The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.
Knorr J; Wree A; Tacke F; Feldstein AE
Semin Liver Dis; 2020 Aug; 40(3):298-306. PubMed ID: 32526788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
